Replies to post #59 on Amarantus Bioscience Holdings Inc (AMBS)

[Komando Robot]

Full Due Diligence Sheet ~



Amarantus BioSciences, Inc.

(OTCBB: AMBS – $.14 per share)

www.amarantus.com

Market Value1: $10,532,123 a/o Dec 08, 2011

A/S: 250 million per last 10- Q 11/17/2011

: O/S 81,016,330 per last 10-Q 11/17/2011

52-Week High / $2.25

52-Week Low / $.06

Average Price/ .1487 (50-day) .2058 (200-day)

Average Volume / 20,499 (50-day) 55,029 (200-day)

Amarantus BioSciences Targets $3 Billion Global Market using its Patented and Proprietary MANF Platform to Treat Parkinson’s Disease

Pre-clinical Experiment Funded from the Michael J. Fox Foundation for Parkinson’s Research Confirms Potential for Benefits

Recent News: Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration

After last week’s announcement that Gilead Sciences (GILD) will acquire Pharmasset (VRUS) in an all cash $11 billion takeover, investors are searching for other biotech stocks that could be next. Cash from the huge transaction is likely to find a home in a slew of up and coming biotech stocks. "These deals tend to happen in waves," says Dan Veru, Palisade Capital Management's chief investment officer.

Amarantus BioSciences, Inc.

(OTCBB: AMBS – $.14 per share)

www.amarantus.com

Common Shares Outstanding / 67.02M

Market Cap / $11.39M

52-Week High / $2.25

52-Week Low / $.06

Average Price/ .1487 (50-day) .2058 (200-day)

Average Volume / 20,499 (50-day) 55,029 (200-day)

Amarantus BioSciences Targets $3 Billion Global Market using its Patented and Proprietary MANF Platform to Treat Parkinson’s Disease

Pre-clinical Experiment Funded from the Michael J. Fox Foundation for Parkinson’s Research Confirms Potential for Benefits

Recent News: Amarantus BioSciences and Banyan Biomarkers announce Traumatic Brain Injury Research Collaboration

Sizzling Stock Picks Trading Notes:

After last week’s announcement that Gilead Sciences (GILD) will acquire Pharmasset (VRUS) in an all cash $11 billion takeover, investors are searching for other biotech stocks that could be next. Cash from the huge transaction is likely to find a home in a slew of up and coming biotech stocks. "These deals tend to happen in waves," says Dan Veru, Palisade Capital Management's chief investment officer.

AMBS is a fully reporting OTC Bulletin Board listed stock. Active trading took place in AMBS shortly after it began to trade publicly in late July / early August at prices between .23 and .48 per share. After hitting about .40 in mid-August, AMBS pulled back to trade in a range from mid-August through the end of October primarily between .10 and .20 per share.

Parkinson’s disease affects more than a million people in the United States alone and remains a disease with no cure.

Amarantus BioSciences has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF").

Although Amarantus was founded in January 2008, it acquired the data and assets from its predecessor from Canada. The previous Company successfully raised over $12 million, and although that Company took a wrong path, previous successes and errors provide extremely valuable information for AMBS going forward.

Who knows the future for AMBS, but a $50 to $100 million valuation would put AMBS at a price of .74 to $1.49 per share at the current share count.







AMBS Business Desrciption

Amarantus BioSciences, Inc. (“Amarantus”) is focused on the discovery and development of therapeutic proteins with the potential to address critically important biological pathways involved in the treatment human diseases.

The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders. With a global trend towards an prolonged life expectancy due to novel therapies and emerging countries gaining access to critical medical care, the development of Apoptosis-related treatments represents a significant market opportunity that addresses a critical unmet medical need: safely and effectively improving currently-approved patients treatments.

Amarantus’ business strategy, utilizing Amarantus’ seasoned Management Team, world-class Scientific Advisory Board and Board of Directors, is to employ our PhenoGuard Drug Discovery Engine to discover medically-relevant secreted human proteins, scientifically establish their therapeutic potential, develop pre-clinical and clinical programs to further their development, and advance them through successive de-risking milestones to maximize their commercial potential while making them attractive partnering targets for product development focused biotechnology, pharmaceutical, medical device and diagnostic companies



PhenoGuard Cell Line Library

Amarantus Therapeutics has pioneered the development of immortalized mammalian cells that retain the phenotype of their parent cell. Our proprietary PhenoGuard immortalization process, which does not utilize Genetic Engineering techniques to insert foreign DNA into the genome, allows for the development of cell lines from both dividing and non-dividing cell that express the same genes as their Parent cells.

To date, Amarantus has developed a library of 80 cell lines engineering from Astrocytes and Neurons from various regions of the Central Nervous System. Our lead candidate AMRS001 was derived from the very PhenoGuard Cell Line ever developed. Amarantus intends to use this resource to advance Therapeutic Discovery and Target Validation.

PhenoGuard Protein Discovery Engine

Amarantus Therapeutics has developed a robust discovery platform PhenoGuard Protein Discovery Engine that allows Amarantus scientists to rapidly discover novel secreted human proteins with biological activity for specific indications. Our Platform consists of our PhenoGuard Cell Line Library and highly sensitive Target Validation cell culture systems that provide accurate results and allow our scientists to make better go/no-go decisions. The first application of our Protein Discovery Engine was in the discovery of MANF from astrocytes.

“On September 29, 2011, the United States Patent and Trademark Office gave its Notice of Allowance of our U.S. Patent Application No.
12/535,029, Dopaminergic Nueronal Survival – Promoting Factors and Used Thereof. The patent application claims include the discovery of
mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF is a highly potent, neurotrophic factor currently in pre-clinical
development for the treatment of a range of diseases apoptosis-related including Parkinson's disease. The patent will broaden overall protection
for our therapeutic development of MANF. The patent claims include compositions of matter and methods of use for MANF, and other related
compounds. Issuance of this new patent will complement our existing collection of issued patents throughout Europe and pending patent
applications worldwide on our proprietary MANF platform.

About MANF

MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property
provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF
product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox
Foundation for Parkinson’s Research. The Company also owns an inventory of 88 cell lines refered to as “PhenoGuard Cell Lines.” MANF
was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for
various therapeutic approaches to the Central Nervous System will be identified from the Company’s inventory of PhenoGuard Cell Lines.



Apoptosis

Apoptosis is the term used to describe Programmed Cell Death (PCD) in multicellular organisms. Apoptosis is one of the main types of PCD which involves a cascade of biochemical events leading to specific changes in the cell at the level of the nucleus, cytoplasm and plasma membrane, ultimately to cell death.
Apoptosis differs from necrosis, the other major type of cell death, in that the processes associated with apoptosis in disposal of cellular debris tend not to induce inflammation and further damage to the organism as a whole. Necrosis is a form of traumatic cell death that results from acute cellular injury. Apoptosis in contrast to necrosis, confers advantages during an organism’s life cycle. Since the 1990's research has increased substantially in the field of apoptosis. It has been shown that defective apoptotic processes in humans and animals are related to a variety of diseases. Excessive apoptosis has been implicated in neurodegenerative diseases like Parkinson’s and Alzheimer’s diseases, and diseases resulting from ischemic damage. Deficient apoptosis on the other hand can lead to uncontrolled cell proliferation, as occurs in cancer.
The development and careful application of therapies that mediate this a verity of severe disorders

Astrocytes

Proliferation of DA Neuron by of two PhenoGuard
Astrocytes are brain cells that make up a large portion of the cells in the Central Nervous System. Generally speaking, the function of astrocytes is support neurons throughout their development. The support they provide is localized, which means that astrocytes from a specific brain region act more powerfully on neurons from that particular brain region than from any other. Astrocytes mediate three critical brain functions:
1. Neuroprotection: Helping to protect neurons from death
2. Neurogenesis: Helping to generate new neurons from stem cells
3. Synaptogenesis: Helping to establish connections between neurons
Astrocytes perform these tasks by producing and secreting molecules that affect neurons. Using our proprietary method, we are able to identify these highly relevant proteins with biological activity for the protection of neurons and other cells associated with the treatment of devastating human disorders. The first drug candidate identified from this platform is MANF

Partners

Partnering Business Model

Amarantus BioSciences believes that it has far more viable development opportunities than any single company could adequately exploit. As such, Amarantus intends to partner product development with leading academic institutions, research institutes, hospitals, clinics, small to large scale biotechnology, pharmaceutical, diagnostic and device companies to achieve maximum value creation for its high-value, multi-purposed discoveries.

Amarantus BioSciences is interested in partnering opportunities for its product candidates that will allow development of adjunct -products that will address diseases caused by poorly served biological pathways. We intend to generate revenues through collecting up-front and milestone payments as our candidates advance through pre-clinical and clinical development, and royalties upon commercialization.



PhenoGuard Cell Line Library

Amarantus Therapeutics has pioneered the development of immortalized mammalian cells that retain the phenotype of their parent cell. Our proprietary PhenoGuard immortalization process, which does not utilize Genetic Engineering techniques to insert foreign DNA into the genome, allows for the development of cell lines from both dividing and non-dividing cell that express the same genes as their Parent cells.
To date, Amarantus has developed a library of 80 cell lines engineering from Astrocytes and Neurons from various regions of the Central Nervous System. Our lead candidate AMRS001 was derived from the very PhenoGuard Cell Line ever developed. Amarantus intends to use this resource to advance Therapeutic Discovery and Target Validation.

PhenoGuard Protein Discovery Engine

Amarantus Therapeutics has developed a robust discovery platform PhenoGuard Protein Discovery Engine that allows Amarantus scientists to rapidly discover novel secreted human proteins with biological activity for specific indications. Our Platform consists of our PhenoGuard Cell Line Library and highly sensitive Target Validation cell culture systems that provide accurate results and allow our scientists to make better go/no-go decisions. The first application of our Protein Discovery Engine was in the discovery of MANF from astrocytes.
Amarantus Therapeutics at the 2010 OneMedForum

[img]http://www.stockgoodies.com/m/photos/get_image/file/b16a762164c76a7cb95239da4131837e.jpg[/img

http://www.youtube.com/watch?v=lT-F9WYxLjo




Security Details

Amarantus Biosciences, Inc.

is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, “AMBS”, and within the OTCQB market tier. As such, Business, operational and financial information on AMBS is fully transparent and available to public view.

Visit http://www.otcmarkets.com/stock/AMBS/quote for more information.

(some of the information on the information page is not correct we have used the SEC filings for most of our information posted here)

Market Value1: $10,532,123 a/o Dec 08, 2011

A/S: 250 million per last 10- Q 11/17/2011

O/S : 81,016,330 per last 10-Q 11/17/2011

Transfer Agent

Empire Stock Transfer Inc.

1859 Whitney Mesa Dr.

Henderson, NV, 89014

702-818-5898

www.empirestock.com



10Q reported11/17/2011 period ending 9/30/2011

Shareholders of Record: 35 a/o Jun 14, 2010

SIC - Industry Classification: 2834 - Pharmaceutical preparations

Incorporated In: DE, USA

Year of Inc.: 2008 per last 10-Q Filed 11/17/2011

Security Notes: * Capital Change=shs increased by 25 for 1 split. Ex-date=06/14/2011. Rec date=06/06/2011. Pay date=06/13/2011.


Source: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com

(these are only sources and not always up to date)



Amarantus BioSciences to Present at the National Investment Banking Association’s (NIBA) 120th Investment ConferenceBusiness Wire(Thu, Dec 1)
Amarantus BioSciences Receives Grant from Brewer Sports International for Traumatic Brain InjuryBusiness Wire(Wed, Nov 30)
New Webcast Interview With President and CEO Gerald Commissiong Now Available at TheGreenBaron.comGlobeNewswire(Tue, Nov 29)
Amarantus Biosciences and Banyan Biomarkers Announce Traumatic Brain Injury Research CollaborationBusiness Wire(Tue, Nov 22)
AMARANTUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Nov 17)
Amarantus BioSciences’ Gerald and Dr. John Commissiong Selected as Black Money’s “50 Most Important African-Americans in Technology”Business Wire(Tue, Nov 15)
Amarantus Biosciences, a Promising Biotech Company in DevelopmentGlobeNewswire(Mon, Nov 14)
Amarantus BioSciences Expands Corporate StrategyBusiness Wire(Tue, Nov 1)
Amarantus BioSciences Appoints Gerald Commissiong President & CEOBusiness Wire(Fri, Oct 28)
AMARANTUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Oct 27)





Management Team

Gerald E. Commissiong

President & CEO

Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus Financial Decisions from Stanford University.

John W. Commissiong, PhD

Chief Scientific Officer

Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009. From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.

Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.

Marc E. Faerber

Controller / Chief Financial Officer Controller

Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology, gastroenterology, orthopedics, diagnostics and biotechnology.

Mr. Faerber has extensive transactional experience, including considerable experience in establishing international organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers and acquisitions, and numerous funding transactions, including an initial public offering as well as other international business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a Bachelor of Sciences in Business Administration from Providence College.



Contact Info

Amarantus BioSciences, Inc.
675 Almanor Avenue
Sunnyvale, CA 94085
United States - Map
Phone: [phone]
Fax: [phone]
Website: http://www.amarantus.com




This alert brought to you by SizzlingStockPicks

Follow Us on Twitter

https://twitter.com/#!/SizzlinStockPix

Follow Sizzling Stock Picks Blog

http://sizzlingstockpicks.blogspot.com/

Follow Us on Facebook

http://www.facebook.com/groups/SizzlingStockPicks/

Disclaimer below:

http://sizzlingstockpicks.com/disclaimer.php

NEED AWARENESS??

Contact Us:

[e-mail]

[Penny Roger$]

This is on radar for Monday. -Low float alert- $AMBS IHUB has the float listed at 21.5 million!